Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin

Donnette A. Dabydeen, James C. Burnett, Ruoli Bai, Pascal Verdier-Pinard, Sarah J H Hickford, George Pettit, John W. Blunt, Murray H G Munro, Rick Gussio, Ernest Hamel

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

The complex marine natural product halichondrin B was compared with NSC 707389 (E7389), a structurally simplified, synthetic macrocyclic ketone analog, which has been selected for clinical trials in human patients. NSC 707389 was invariably more potent than halichondrin B in its interactions with tubulin. Both compounds inhibited tubulin assembly, inhibited nucleotide exchange on β-tubulin, and were noncompetitive inhibitors of the binding of radiolabeled vinblastine and dolastatin 10 to tubulin. Neither compound seemed to induce an aberrant tubulin assembly reaction, as occurs with vinblastine (tight spirals) or dolastatin 10 (aggregated rings and spirals). We modeled the two compounds into a shared binding site on tubulin consistent with their biochemical properties. Of the two tubulin structures available, we selected for modeling the complex of a stathmin fragment with two tubulin heterodimers with two bound colchicinoid molecules and a single bound vinblastine between the two heterodimers (Nature (Lond) 435:519-522, 2005). Halichondrin B and NSC 707389 fit snugly between the two heterodimers adjacent to the exchangeable site nucleotide. Fitting the compounds into this site, which was also close to the vinblastine site, resulted in enough movement of amino acid residues at the vinblastine site to cause the latter compound to bind less well to tubulin. The model suggests that halichondrin B and NSC 707389 most likely form highly unstable, small aberrant tubulin polymers rather than the massive stable structures observed with vinca alkaloids and antimitotic peptides.

Original languageEnglish (US)
Pages (from-to)1866-1875
Number of pages10
JournalMolecular Pharmacology
Volume70
Issue number6
DOIs
StatePublished - 2006

Fingerprint

eribulin
Tubulin
Binding Sites
Vinblastine
dolastatin 10
Nucleotides
Stathmin
halichondrin B
Vinca Alkaloids
Antimitotic Agents

ASJC Scopus subject areas

  • Pharmacology

Cite this

Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. / Dabydeen, Donnette A.; Burnett, James C.; Bai, Ruoli; Verdier-Pinard, Pascal; Hickford, Sarah J H; Pettit, George; Blunt, John W.; Munro, Murray H G; Gussio, Rick; Hamel, Ernest.

In: Molecular Pharmacology, Vol. 70, No. 6, 2006, p. 1866-1875.

Research output: Contribution to journalArticle

Dabydeen, DA, Burnett, JC, Bai, R, Verdier-Pinard, P, Hickford, SJH, Pettit, G, Blunt, JW, Munro, MHG, Gussio, R & Hamel, E 2006, 'Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin', Molecular Pharmacology, vol. 70, no. 6, pp. 1866-1875. https://doi.org/10.1124/mol.106.026641
Dabydeen, Donnette A. ; Burnett, James C. ; Bai, Ruoli ; Verdier-Pinard, Pascal ; Hickford, Sarah J H ; Pettit, George ; Blunt, John W. ; Munro, Murray H G ; Gussio, Rick ; Hamel, Ernest. / Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. In: Molecular Pharmacology. 2006 ; Vol. 70, No. 6. pp. 1866-1875.
@article{ac3fc5a1a6d845709afd922812b0f655,
title = "Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin",
abstract = "The complex marine natural product halichondrin B was compared with NSC 707389 (E7389), a structurally simplified, synthetic macrocyclic ketone analog, which has been selected for clinical trials in human patients. NSC 707389 was invariably more potent than halichondrin B in its interactions with tubulin. Both compounds inhibited tubulin assembly, inhibited nucleotide exchange on β-tubulin, and were noncompetitive inhibitors of the binding of radiolabeled vinblastine and dolastatin 10 to tubulin. Neither compound seemed to induce an aberrant tubulin assembly reaction, as occurs with vinblastine (tight spirals) or dolastatin 10 (aggregated rings and spirals). We modeled the two compounds into a shared binding site on tubulin consistent with their biochemical properties. Of the two tubulin structures available, we selected for modeling the complex of a stathmin fragment with two tubulin heterodimers with two bound colchicinoid molecules and a single bound vinblastine between the two heterodimers (Nature (Lond) 435:519-522, 2005). Halichondrin B and NSC 707389 fit snugly between the two heterodimers adjacent to the exchangeable site nucleotide. Fitting the compounds into this site, which was also close to the vinblastine site, resulted in enough movement of amino acid residues at the vinblastine site to cause the latter compound to bind less well to tubulin. The model suggests that halichondrin B and NSC 707389 most likely form highly unstable, small aberrant tubulin polymers rather than the massive stable structures observed with vinca alkaloids and antimitotic peptides.",
author = "Dabydeen, {Donnette A.} and Burnett, {James C.} and Ruoli Bai and Pascal Verdier-Pinard and Hickford, {Sarah J H} and George Pettit and Blunt, {John W.} and Munro, {Murray H G} and Rick Gussio and Ernest Hamel",
year = "2006",
doi = "10.1124/mol.106.026641",
language = "English (US)",
volume = "70",
pages = "1866--1875",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "6",

}

TY - JOUR

T1 - Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin

AU - Dabydeen, Donnette A.

AU - Burnett, James C.

AU - Bai, Ruoli

AU - Verdier-Pinard, Pascal

AU - Hickford, Sarah J H

AU - Pettit, George

AU - Blunt, John W.

AU - Munro, Murray H G

AU - Gussio, Rick

AU - Hamel, Ernest

PY - 2006

Y1 - 2006

N2 - The complex marine natural product halichondrin B was compared with NSC 707389 (E7389), a structurally simplified, synthetic macrocyclic ketone analog, which has been selected for clinical trials in human patients. NSC 707389 was invariably more potent than halichondrin B in its interactions with tubulin. Both compounds inhibited tubulin assembly, inhibited nucleotide exchange on β-tubulin, and were noncompetitive inhibitors of the binding of radiolabeled vinblastine and dolastatin 10 to tubulin. Neither compound seemed to induce an aberrant tubulin assembly reaction, as occurs with vinblastine (tight spirals) or dolastatin 10 (aggregated rings and spirals). We modeled the two compounds into a shared binding site on tubulin consistent with their biochemical properties. Of the two tubulin structures available, we selected for modeling the complex of a stathmin fragment with two tubulin heterodimers with two bound colchicinoid molecules and a single bound vinblastine between the two heterodimers (Nature (Lond) 435:519-522, 2005). Halichondrin B and NSC 707389 fit snugly between the two heterodimers adjacent to the exchangeable site nucleotide. Fitting the compounds into this site, which was also close to the vinblastine site, resulted in enough movement of amino acid residues at the vinblastine site to cause the latter compound to bind less well to tubulin. The model suggests that halichondrin B and NSC 707389 most likely form highly unstable, small aberrant tubulin polymers rather than the massive stable structures observed with vinca alkaloids and antimitotic peptides.

AB - The complex marine natural product halichondrin B was compared with NSC 707389 (E7389), a structurally simplified, synthetic macrocyclic ketone analog, which has been selected for clinical trials in human patients. NSC 707389 was invariably more potent than halichondrin B in its interactions with tubulin. Both compounds inhibited tubulin assembly, inhibited nucleotide exchange on β-tubulin, and were noncompetitive inhibitors of the binding of radiolabeled vinblastine and dolastatin 10 to tubulin. Neither compound seemed to induce an aberrant tubulin assembly reaction, as occurs with vinblastine (tight spirals) or dolastatin 10 (aggregated rings and spirals). We modeled the two compounds into a shared binding site on tubulin consistent with their biochemical properties. Of the two tubulin structures available, we selected for modeling the complex of a stathmin fragment with two tubulin heterodimers with two bound colchicinoid molecules and a single bound vinblastine between the two heterodimers (Nature (Lond) 435:519-522, 2005). Halichondrin B and NSC 707389 fit snugly between the two heterodimers adjacent to the exchangeable site nucleotide. Fitting the compounds into this site, which was also close to the vinblastine site, resulted in enough movement of amino acid residues at the vinblastine site to cause the latter compound to bind less well to tubulin. The model suggests that halichondrin B and NSC 707389 most likely form highly unstable, small aberrant tubulin polymers rather than the massive stable structures observed with vinca alkaloids and antimitotic peptides.

UR - http://www.scopus.com/inward/record.url?scp=33751102419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751102419&partnerID=8YFLogxK

U2 - 10.1124/mol.106.026641

DO - 10.1124/mol.106.026641

M3 - Article

C2 - 16940412

AN - SCOPUS:33751102419

VL - 70

SP - 1866

EP - 1875

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 6

ER -